Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-03-08-Speech-2-254-500"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110308.22.2-254-500"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"On the basis of statistical data presented in this report, the reaction to the spread of H1N1 was actually disproportionate to the actual nature of the phenomenon, generating, in fact, very costly vaccination campaigns in many Member States. The rapporteur therefore considered it appropriate to raise extremely important issues, first of all, concerning the overwhelming influence of pharmaceutical companies. She urged that studies on antiviral medications should be independent of pharmaceutical companies. The accelerated authorisation procedures have demonstrated their limitations, because no scientific evidence is available and data released by the industry are therefore still used. There is also need for better cooperation, to request a review of prevention plans and the roles of key actors, and also to enable Member States to make group purchases on a voluntary basis. The World Health Organisation (WHO) should revise its definition of a pandemic as soon as possible so as to include the virulence of the virus in its classification. In this regard, it is necessary that the vaccine should be effective, have a positive relationship between risks and benefits, and be genuinely targeted at risk groups. Finally, we must avoid any conflicts of interest because they may immediately generate suspicion of undue pressure in public opinion."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples